8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 16, 2026·SEC
Zenas BioPharma, Inc.(ZBIO)Earnings, Financials & Key Ratios
ZBIO•NASDAQ
$24.67
Price updated Jun 25, 2026
AboutZenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.Show more
- Revenue$10M+100.0%
- EBITDA-$211M-29.1%
- Net Income-$378M-140.6%
- EPS (Diluted)-8.44-124.5%
- Gross Margin100%+103.7%
- EBITDA Margin-2113.29%+35.5%
- Operating Margin-2113.85%+35.5%
- Net Margin-3777.37%-20.3%
- ROE-136.22%+62.4%
ZBIO Price & Volume
Zenas BioPharma, Inc. (ZBIO) stock price & volume — 10-year historical chart
Loading chart...
ZBIO Growth Metrics
Zenas BioPharma, Inc. (ZBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-161.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-129.22%
Return on Capital
10 Years-98.64%
5 Years-98.64%
3 Years-79.27%
Last Year-66.72%
ZBIO Recent Earnings
Zenas BioPharma, Inc. (ZBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.46-6.6%
$1.37
Rev
—
$25M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$1.10-9.8%
$1.00
Rev
—
$13M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.22-40.2%
$0.87
Rev
—
$29M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$1.25-22.5%
$1.02
Rev
—
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.46vs $1.37-6.6% | —vs $25M |
| Q2 2026 | Mar 16, 2026 | $1.10vs $1.00-9.8% | —vs $13M |
| Q4 2025 | Nov 12, 2025 | $1.22vs $0.87-40.2% | —vs $29M |
| Q3 2025 | Aug 12, 2025 | $1.25vs $1.02-22.5% | —vs $4M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Zenas BioPharma, Inc. (ZBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.67 | $1.1B | -2.92 | 100% | -3777.37% | -136.22% | — | |
| $6.82 | $193.85M | -2.84 | -51.43% | -173.47% | -36.55% | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $6.06 | $1.49B | -23.31 | 22.09% | -13.58% | -38.11% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $116.46 | $9.51B | -31.56 | -16.72% | -612.17% | -25.02% | — |
Compare ZBIO vs Peers
Zenas BioPharma, Inc. (ZBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZBIO SEC Filings & Documents
Zenas BioPharma, Inc. (ZBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ZBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZBIO Frequently Asked Questions
Zenas BioPharma, Inc. (ZBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Zenas BioPharma, Inc.'s revenue?
Zenas BioPharma, Inc. (ZBIO) reported $10.0M in revenue for fiscal year 2025.
How fast is Zenas BioPharma, Inc. growing?
Zenas BioPharma, Inc. (ZBIO) grew revenue by 100.0% over the past year. This is strong growth.
Is ZBIO profitable?
Zenas BioPharma, Inc. (ZBIO) reported a net loss of $425.2M for fiscal year 2025.
Dividend & Returns
What is ZBIO's return on equity?
Zenas BioPharma, Inc. (ZBIO) has a return on equity (ROE) of -136.2%. Negative ROE indicates the company is unprofitable.
What is Zenas BioPharma, Inc.'s free cash flow?
Zenas BioPharma, Inc. (ZBIO) had negative free cash flow of $210.5M in fiscal year 2025, likely due to heavy capital investments.